Eli Lilly's Quarter Was Messy. What To Do With The Stock Is Clear-Cut

Eli Lilly shares fell Wednesday after the diabetes-and-obesity drug giant posted disappointing third-quarter results and lowered its full-year sales guidance. The report was messy, but it doesn't dim Eli Lilly's bright multiyear outlook, rendering th ...Read more